Review Reports
- Huixia Wang †,
- Ruifeng Zhong † and
- Yali Li *
- et al.
Reviewer 1: Anonymous Reviewer 2: Attilio Corradi Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for Authors-
The study identifies miR-214-3p as a key regulator that protects porcine intestinal epithelial cells from imipramine (IMI)-induced lysosomal dysfunction by targeting cathepsin D (CTSD).
-
The Simple Summary and Abstract effectively outline the study's goal of elucidating how miRNAs govern lysosomal homeostasis in neonatal piglets, specifically using the IMI-induced dysfunction model.
-
While the manuscript identifies CTSD as the primary target, the methodology for initial miRNA selection from the 17 differentially expressed miRNAs (5 up-regulated and 12 down-regulated) could be more clearly justified beyond the pathway-union analysis shown in Figure 1.
Figure 1F validates the down-regulation of miR-214-3p in piglets treated with IMI via qRT-PCR, but the sample size (n=3) is relatively small for definitive in vivo conclusions.
-
The results in Figure 2 and Figure 3 demonstrate that the miR-214-3p mimic restores cell viability and migration impaired by IMI (75 µM), providing robust evidence for its cytoprotective role.
-
The apoptosis data in Figure 4 is well-supported by both flow cytometry (AV-APC/PI) and the expression levels of pro-apoptotic genes like BAX, FAS, and TP53.
-
In Figure 5, the authors clarify that miR-214-3p does not influence IMI-induced endocytosis or mitophagy, which effectively narrows the mechanism to specific lysosomal maintenance.
-
The measurement of lysosomal pH using the LysoSensor probe and ACP activity in Figure 6 provides critical physiological context for the "alkalinization" mentioned in the text.
Figure 7 and Figure 8 use Acridine Orange (AO) staining and TFEB immunofluorescence to show that miR-214-3p preserves membrane integrity and inhibits the stress-induced nuclear translocation of TFEB.
-
The Dual-luciferase reporter assay in Figure 9 convincingly validates that miR-214-3p directly binds to the 3' UTR of CTSD, as the mutation of the binding site abolished the inhibitory effect.
Figure 10 provides a necessary "rescue" experiment, showing that overexpressing CTSD reverses the beneficial effects of the miR-214-3p mimic on ACP activity and LAMP1 levels.
-
The Discussion appropriately places the findings within the context of existing literature, such as the roles of miR-214 in cancer and other inflammatory models.
-
A potential limitation is the reliance on imipramine (IMI) as the sole model for lysosomal dysfunction; while IMI is a standard cationic amphiphilic drug for this purpose, acknowledging other potential stressors would strengthen the study's broader relevance.
-
The Conclusion summarizes the miR-214-3p-CTSD-lysosome axis as a potential therapeutic target for neonatal piglet intestinal health, which is logically derived from the presented data.
-
There are minor inconsistencies in font or formatting in the Abbreviations section (e.g., "3prime UTR" versus "3' UTR") that should be standardized for the final publication.
Author Response
The study identifies miR-214-3p as a key regulator that protects porcine intestinal epithelial cells from imipramine (IMI)-induced lysosomal dysfunction by targeting cathepsin D (CTSD).
The Simple Summary and Abstract effectively outline the study's goal of elucidating how miRNAs govern lysosomal homeostasis in neonatal piglets, specifically using the IMI-induced dysfunction model.
Response: We are grateful for the reviewer’s favorable assessment.
While the manuscript identifies CTSD as the primary target, the methodology for initial miRNA selection from the 17 differentially expressed miRNAs (5 up-regulated and 12 down-regulated) could be more clearly justified beyond the pathway-union analysis shown in Figure 1.
Response: We thank the reviewer for their valuable comments and we have revised Figure 1 accordingly.
Figure 1F validates the down-regulation of miR-214-3p in piglets treated with IMI via qRT-PCR, but the sample size (n=3) is relatively small for definitive in vivo conclusions.
Response: Thank you for your insightful comment. We acknowledge this limitation, as noted in the Conclusion section, P17, Lines 483-486. To minimize genetic variability, a major confounding factor in in vivo studies, we selected six healthy newborn female piglets from the same litter (since sows in our research facility average ~12 viable piglets), allocating three to each group. This design aimed to reduce genetic background variation for a focused assessment of treatment effects. However, we agree that n = 3 per group limits statistical power and inter-individual variability assessment. Thus, the miRNA-seq findings should be interpreted as qualitative and hypothesis-generating, not definitive quantitative conclusions. We have stated this limitation in the revised manuscript, emphasizing that future studies with larger cohorts are necessary to validate these preliminary findings and to better capture biological variability across individuals. We thank the reviewer again for helping us improve the scientific rigor of our report.
The results in Figure 2 and Figure 3 demonstrate that the miR-214-3p mimic restores cell viability and migration impaired by IMI (75 µM), providing robust evidence for its cytoprotective role.
The apoptosis data in Figure 4 is well-supported by both flow cytometry (AV-APC/PI) and the expression levels of pro-apoptotic genes like BAX, FAS, and TP53.
In Figure 5, the authors clarify that miR-214-3p does not influence IMI-induced endocytosis or mitophagy, which effectively narrows the mechanism to specific lysosomal maintenance.
The measurement of lysosomal pH using the LysoSensor probe and ACP activity in Figure 6 provides critical physiological context for the "alkalinization" mentioned in the text.
Figure 7 and Figure 8 use Acridine Orange (AO) staining and TFEB immunofluorescence to show that miR-214-3p preserves membrane integrity and inhibits the stress-induced nuclear translocation of TFEB.
The Dual-luciferase reporter assay in Figure 9 convincingly validates that miR-214-3p directly binds to the 3' UTR of CTSD, as the mutation of the binding site abolished the inhibitory effect.
Figure 10 provides a necessary "rescue" experiment, showing that overexpressing CTSD reverses the beneficial effects of the miR-214-3p mimic on ACP activity and LAMP1 levels.
The Discussion appropriately places the findings within the context of existing literature, such as the roles of miR-214 in cancer and other inflammatory models.
Response: We sincerely thank the reviewer for this positive and encouraging comment. We are truly grateful that the Figures and Discussion were found to appropriately present our findings. Your recognition is highly appreciated.
A potential limitation is the reliance on imipramine (IMI) as the sole model for lysosomal dysfunction; while IMI is a standard cationic amphiphilic drug for this purpose, acknowledging other potential stressors would strengthen the study's broader relevance.
Response: Thank you for your valuable and insightful comment. We acknowledge this limitation and have addressed it in the Conclusion section by stating that future studies incorporating additional lysosomal stressors are warranted to validate the broader relevance of our findings, P17, Lines 483-486. In our current data (Figure 6), the inclusion of Baf A1 as a positive control in our pH and ACP assays provides additional support for the observed effects, and future studies incorporating other lysosomal stressors would help establish broader relevance.
The Conclusion summarizes the miR-214-3p-CTSD-lysosome axis as a potential therapeutic target for neonatal piglet intestinal health, which is logically derived from the presented data.
Response: We thank the reviewer for this encouraging comment.
There are minor inconsistencies in font or formatting in the Abbreviations section (e.g., "3prime UTR" versus "3' UTR") that should be standardized for the final publication.
Response: Thank you for your careful review. We have standardized all instances in the Abbreviations section as suggested.
Reviewer 2 Report
Comments and Suggestions for AuthorsDear Authors, the study is well conceptualized as preliminary investigation, combining in vivo and in vitro approaches aimed at identifying a specific regulatory axis, and in particular pinpointing miR‑214‑3p as a key down‑regulated miRNA enriched in lysosome‑related pathways. The study also investigates several lysosomal functions, including pH, ACP activity, lysosomal membrane integrity, LAMP1 expression, and TFEB nuclear translocation.
However, the study has an important limitation regarding the in vivo sample size: only six piglets (n = 3 per group) were used. This small sample size limits the statistical power and robustness of the miRNA‑seq findings and may not adequately capture inter‑individual variability.
Regarding the statistical analysis, another limitation is that some results (e.g., “slight cell shrinkage”, “no significant effect” of the inhibitor) are described qualitatively without extensive quantitative assessment.
I suggest modifying the title to indicate that this is a preliminary study. Another suggestion is to highlight in the “Discussion” and “Conclusion” Chapters the experimental limitations, specifically that the statistical analysis does not allow assessment of individual variability and is therefore mainly qualitative, to the detriment of a more robust quantitative analysis.
Author Response
Dear Authors, the study is well conceptualized as preliminary investigation, combining in vivo and in vitro approaches aimed at identifying a specific regulatory axis, and in particular pinpointing miR‑214‑3p as a key down‑regulated miRNA enriched in lysosome‑related pathways. The study also investigates several lysosomal functions, including pH, ACP activity, lysosomal membrane integrity, LAMP1 expression, and TFEB nuclear translocation.
Response: We are deeply grateful to the reviewer for this positive and constructive feedback.
However, the study has an important limitation regarding the in vivo sample size: only six piglets (n = 3 per group) were used. This small sample size limits the statistical power and robustness of the miRNA‑seq findings and may not adequately capture inter‑individual variability.
Response: Thank you for your valuable and insightful comment regarding the sample size. We fully acknowledge this limitation, as also noted in the Conclusion section of the manuscript, P17, Lines 483-486. To minimize genetic variability, a major confounding factor in in vivo studies, we selected six healthy newborn female piglets from the same litter (since sows in our research facility average ~12 viable piglets), allocating three to each group. This design aimed to reduce genetic background variation for a focused assessment of treatment effects. However, we agree that n = 3 per group limits statistical power and inter-individual variability assessment. Thus, the miRNA-seq findings should be interpreted as qualitative and hypothesis-generating, not definitive quantitative conclusions. We have stated this limitation in the revised manuscript, emphasizing that future studies with larger cohorts are necessary to validate these preliminary findings and to better capture biological variability across individuals. We thank the reviewer again for helping us improve the scientific rigor of our report.
Regarding the statistical analysis, another limitation is that some results (e.g., “slight cell shrinkage”, “no significant effect” of the inhibitor) are described qualitatively without extensive quantitative assessment.
Response: We have revised the manuscript by removing or rephrasing the qualitative descriptions as suggested, P13, Lines 331-332, 335.
I suggest modifying the title to indicate that this is a preliminary study. Another suggestion is to highlight in the “Discussion” and “Conclusion” Chapters the experimental limitations, specifically that the statistical analysis does not allow assessment of individual variability and is therefore mainly qualitative, to the detriment of a more robust quantitative analysis.
Response: Thank you for your insightful suggestions. We have revised the title to “The miR-214-3p/CTSD axis regulates lysosomal homeostasis in porcine intestinal epithelial cells: A preliminary study” to reflect the preliminary nature of this work. We have also highlighted the experimental limitations in the Conclusion section, acknowledging the need for future validation with larger sample sizes and in vivo models, P17, Lines 483-486. We greatly appreciate your help in improving our manuscript.
Reviewer 3 Report
Comments and Suggestions for AuthorsThis study investigates the role of miRNAs in regulating lysosomal homeostasis in the developing intestine, using an imipramine-induced lysosomal dysfunction model in neonatal piglets. The authors identify ssc-miR-214-3p as a downregulated miRNA associated with lysosomal pathways and demonstrate, through IPEC-J2 cell experiments, that miR-214-3p ameliorates IMI-induced cytotoxicity by restoring lysosomal function, including pH balance, ACP activity, and membrane integrity. Mechanistically, cathepsin D (CTSD) is validated as a direct target of miR-214-3p, and its overexpression reverses the protective effects of the miRNA mimic.
Overall, the study provides interesting insights into a potential miR-214-3p/CTSD regulatory axis in intestinal lysosomal homeostasis. However, several aspects, including in vivo validation, the specificity of the model, and the comprehensiveness of functional assays, require further clarification to strengthen the conclusions.
1.While the in vitro findings in IPEC-J2 cells are compelling, the physiological relevance of the proposed mechanism would be significantly strengthened by in vivo validation. Could the authors further elaborate on whether modulation of miR-214-3p (e.g., via mimic or inhibitor approaches) can directly restore lysosomal function and improve intestinal physiology in the IMI-treated neonatal piglet model? Such evidence would help confirm the translational significance of the miR-214-3p–mediated regulatory pathway in a more physiologically relevant context.
2.The identification of CTSD as a direct target of miR-214-3p is interesting; however, the current evidence may not be sufficient to fully establish CTSD as the primary functional mediator. It would be helpful if the authors could perform complementary loss-of-function experiments, such as CTSD knockdown, to determine whether suppression of CTSD recapitulates the protective effects observed with the miR-214-3p mimic. Additionally, considering that miRNAs often regulate multiple targets, could the authors discuss or experimentally address the potential contribution of other lysosome-related targets?
3.The study evaluates lysosomal function mainly through pH changes and ACP activity, which, while informative, may not fully capture the complexity of lysosomal function. To strengthen the conclusions, could the authors consider including additional functional assays, such as measurements of lysosomal degradation capacity or autophagic flux (e.g., LC3-II and p62 turnover)? These complementary approaches would provide a more comprehensive assessment of lysosomal restoration.
4.Imipramine is known to induce lysosomal dysfunction; however, it may also exert broader cytotoxic effects, which could complicate data interpretation. Could the authors clarify how they distinguish lysosome-specific effects from general cytotoxicity in their model? Furthermore, it would be valuable to assess whether similar results can be reproduced using alternative lysosomal inhibitors (e.g., chloroquine or bafilomycin A1), which would strengthen the robustness and specificity of the findings.
5.The observed restoration of LAMP1 expression is interesting; however, its functional significance in the context of lysosomal recovery remains somewhat unclear. Could the authors clarify whether changes in LAMP1 are functionally linked to lysosomal activity, or whether LAMP1 primarily serves as a correlative marker in this setting? Providing additional functional evidence or discussion would help to better interpret this aspect of the data.
Author Response
This study investigates the role of miRNAs in regulating lysosomal homeostasis in the developing intestine, using an imipramine-induced lysosomal dysfunction model in neonatal piglets. The authors identify ssc-miR-214-3p as a downregulated miRNA associated with lysosomal pathways and demonstrate, through IPEC-J2 cell experiments, that miR-214-3p ameliorates IMI-induced cytotoxicity by restoring lysosomal function, including pH balance, ACP activity, and membrane integrity. Mechanistically, cathepsin D (CTSD) is validated as a direct target of miR-214-3p, and its overexpression reverses the protective effects of the miRNA mimic.
Overall, the study provides interesting insights into a potential miR-214-3p/CTSD regulatory axis in intestinal lysosomal homeostasis. However, several aspects, including in vivo validation, the specificity of the model, and the comprehensiveness of functional assays, require further clarification to strengthen the conclusions.
Response: Thank you for your valuable work in reviewing our manuscript. We have carefully addressed all of your comments and suggestions.
1.While the in vitro findings in IPEC-J2 cells are compelling, the physiological relevance of the proposed mechanism would be significantly strengthened by in vivo validation. Could the authors further elaborate on whether modulation of miR-214-3p (e.g., via mimic or inhibitor approaches) can directly restore lysosomal function and improve intestinal physiology in the IMI-treated neonatal piglet model? Such evidence would help confirm the translational significance of the miR-214-3p–mediated regulatory pathway in a more physiologically relevant context.
Response: We sincerely thank the reviewer for this insightful and constructive suggestion. We fully agree that in vivo modulation of miR-214-3p, via mimic or inhibitor approaches, would provide compelling evidence to confirm the physiological relevance of the miR-214-3p. However, we would like to respectfully note that the systemic administration of miRNA mimics or inhibitors in neonatal piglets involves substantial technical and financial constraints. Given these practical considerations, we are currently planning to validate this mechanism using a mouse model, which offers a more cost-effective and technically feasible platform for in vivo miR-214-3p modulation. Accordingly, we have acknowledged it in the revised Conclusion section (P17, Lines 483-486) as follows: “Future studies incorporating additional lysosomal stressors and larger in vivo cohorts are warranted to validate the broader relevance of the miR-214-3p/CTSD axis in lysosomal homeostasis and to confirm whether direct modulation of miR-214-3p restores lysosomal function and improves intestinal physiology in vivo.” We appreciate your careful review and thank you for helping us improve the clarity and rigor of our manuscript.
2.The identification of CTSD as a direct target of miR-214-3p is interesting; however, the current evidence may not be sufficient to fully establish CTSD as the primary functional mediator. It would be helpful if the authors could perform complementary loss-of-function experiments, such as CTSD knockdown, to determine whether suppression of CTSD recapitulates the protective effects observed with the miR-214-3p mimic. Additionally, considering that miRNAs often regulate multiple targets, could the authors discuss or experimentally address the potential contribution of other lysosome-related targets?
Response: Thank you for these constructive comments. We agree that loss-of-function evidence is needed. While our current data (Figures 9 and 10) identify CTSD as a target gene of miR-214-3p and demonstrate that CTSD overexpression partially reverses the effects induced by the miR-214-3p mimic, future CTSD knockdown experiments and systematic screening of additional lysosome-related targets are needed to fully establish CTSD as the primary functional mediator. This has been explicitly stated in the Discussion section, P17, Lines 472-475. We appreciate your help in strengthening our manuscript. Specifically, we have added the following sentence: “Future studies involving CTSD knockdown are warranted to confirm its role as the primary functional mediator of miR-214-3p, whereas the investigation of additional lysosome-related targets will help to fully elucidate this regulatory network.”
3.The study evaluates lysosomal function mainly through pH changes and ACP activity, which, while informative, may not fully capture the complexity of lysosomal function. To strengthen the conclusions, could the authors consider including additional functional assays, such as measurements of lysosomal degradation capacity or autophagic flux (e.g., LC3-II and p62 turnover)? These complementary approaches would provide a more comprehensive assessment of lysosomal restoration.
Response: Thank you for this constructive suggestion. We agree that assessing autophagic flux (e.g., LC3-II and p62 turnover) would provide a more comprehensive evaluation of lysosomal function. In our current data (Figure 5), the expression of autophagy-related genes MAP1LC3B and BECN1 remained unchanged following miR-214-3p mimic or inhibitor treatment, suggesting that the observed protective effects may not primarily involve autophagy induction at the transcriptional level. Nevertheless, we fully agree that gene expression data may not fully reflect dynamic autophagic flux, and we plan to include appropriate flux assays in future studies to complement our current findings. We have also acknowledged in the revised Discussion section (P16, Lines 428-431) that measurements of lysosomal degradation capacity, as an additional indicator of lysosomal homeostasis, should be included in future studies to provide a more comprehensive functional assessment.
4.Imipramine is known to induce lysosomal dysfunction; however, it may also exert broader cytotoxic effects, which could complicate data interpretation. Could the authors clarify how they distinguish lysosome-specific effects from general cytotoxicity in their model? Furthermore, it would be valuable to assess whether similar results can be reproduced using alternative lysosomal inhibitors (e.g., chloroquine or bafilomycin A1), which would strengthen the robustness and specificity of the findings.
Response: We sincerely thank the reviewer for this important concern regarding the specificity of IMI-induced effects. We fully agree that distinguishing lysosome-specific effects from general cytotoxicity is crucial for accurate data interpretation. First, in our in vivo piglet model (Wang et al., 2025), IMI treatment led to marked morphological alterations in the number and appearance of lysosomes within neonatal intestinal epithelial cells, as observed using transmission electron microscopy. Second, in our in vitro experiments (Figure 6), we included bafilomycin A1 (Baf A1), a well-established lysosomal inhibitor, as a positive control. Notably, Baf A1 treatment produced effects consistent with IMI on lysosomal pH and ACP activity, suggesting that the observed phenotypes are indeed related to lysosomal dysfunction rather than off-target cytotoxicity. Third, our miRNA-seq analysis revealed that the differentially expressed miRNAs were significantly enriched in lysosome-related pathways, further supporting a specific link between miR-214-3p and lysosomal homeostasis. While these data suggest specificity, we agree that testing additional lysosomal inhibitors in future studies would further strengthen this conclusion. We have noted this suggestion in the Conclusion section as part of our future directions, P17, Lines 483-486. We sincerely thank the reviewer for this constructive comment, which has helped us to better clarify the interpretation of our data.
Wang, H., W. Li, Y. Tao, R. Zhong, Y. Li, and H. Yang. 2025. Lysosome dysfunction alters intestinal morphology and lipid metabolism in early neonatal piglets. BMC Vet. Res. 21:604. doi:10.1186/s12917-025-05063-6.
5.The observed restoration of LAMP1 expression is interesting; however, its functional significance in the context of lysosomal recovery remains somewhat unclear. Could the authors clarify whether changes in LAMP1 are functionally linked to lysosomal activity, or whether LAMP1 primarily serves as a correlative marker in this setting? Providing additional functional evidence or discussion would help to better interpret this aspect of the data.
Response: Thank you for your insightful and valuable comment. We acknowledge that the observed restoration of LAMP1 expression primarily reflects preserved lysosomal membrane integrity, given its role as a structural marker, rather than direct functional recovery. We have clarified this point in the revised manuscript (P17, Lines 464-465). In this study, mimic treatment enhanced LAMP1 fluorescence and restored ACP activity, indicating a good correlation between LAMP1 and lysosomal functional recovery. However, based on the current data, we primarily consider LAMP1 as a correlative marker reflecting lysosomal status. Further functional studies (e.g., knockdown or overexpression) would be valuable to clarify its contribution. Thank you again for your thorough review and thoughtful suggestion.
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThey Coverd All my comments
Reviewer 2 Report
Comments and Suggestions for AuthorsDear Authors, the revised manuscript is ready for publication.
Reviewer 3 Report
Comments and Suggestions for AuthorsIt is well revised.